Acutaas Chemicals Ltd

Acutaas Chemicals announced that the Annual General Meeting(AGM) of the company will be held on 25 September 2025.Powered by Capital Market - Live

In Q1 FY26, Acutaas Chemicals reported a 17.3% rise in consolidated revenue from operations at Rs 207.2 crore, up from Rs 176.7 crore in Q1 FY25. Exports contributed 60% while the domestic business accounted for the remaining 40%. Gross profit surged 48.4% YoY to Rs 110.3 crore, expanding the gross margin from 42.1% to 53.2% in Q1 FY26. EBITDA grew 72.4% to Rs 50.9 crore, while net profit (PAT) soared to Rs 44 crore, a 199.6% jump over the same quarter last year. The PAT margin improved from 8.3% to 21.2% in Q1 FY26, reflecting strong operating efficiency. Exports contributed 60% and the domestic business accounting for the remaining 40%. On a sequential basis, performance moderated. The company's consolidated revenue declined 32.8% from Rs 308.5 crore in Q4 FY25. Gross profit dropped 24.4%, while EBITDA fell 40.1% and PAT slipped 29.8% from Q4 FY25. Still, profitability ratios held firm, with EBITDA margin at 24.6% and PAT margin at 21.2% in Q1 FY26, compared to 27.5% and 20.3%, respectively, in Q4 FY25. Both margins saw a sharp improvement from 16.7% EBITDA margin and 8.3% PAT margin in Q1 FY25. Naresh Patel, executive chairman & managing director, Acutaas Chemicals, said: I am happy to share that we've had a strong start to FY26, with Q1 revenue growing 17.3% year-on-year, driven by robust performance in our Pharmaceutical Intermediates business. Both our pharma facilities are now PMDA GMP certified, underscoring our commitment to global compliance and quality. I am happy to announce that we have entered into a joint venture in South Korea which rings us closer to key semiconductor markets and strengthens our portfolio with differentiated, high-value products tailored for this space. With rising customer engagement across COMO, battery chemicals, and semiconductors, we step into FY26 with strong momentum and confidence to deliver 25% growth with improved margins. Acutaas Chemicals (formerly Ami Organics) is a global manufacturer of advanced pharmaceutical intermediates and speciality chemicals. It serves a diverse set of industries, including pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. Powered by Capital Market - Live

Net profit of Acutaas Chemicals rose 217.49% to Rs 44.29 crore in the quarter ended June 2025 as against Rs 13.95 crore during the previous quarter ended June 2024. Sales rose 17.30% to Rs 207.24 crore in the quarter ended June 2025 as against Rs 176.67 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales207.24176.67 17 OPM %24.5716.71 - PBDT66.2126.13 153 PBT58.0819.95 191 NP44.2913.95 217 Powered by Capital Market - Live

Acutaas Chemicals will hold a meeting of the Board of Directors of the Company on 30 July 2025.Powered by Capital Market - Live

Baba Advance Materials (BAML), a wholly owned subsidiary company of Acutaas Chemicals has entered into a joint venture agreement with J & Materials Co., a South Korean Company, whereby BAML shall hold 75% of the share capital of the joint venture company Indichem Inc. (JV Company) a South Korean Company and the remaining 25% of the share capital of the JV Company will be held by J & Materials Co. Powered by Capital Market - Live

Revenue from operations jumped 37.13% year on year to Rs 308.48 crore during the quarter ended 31st March 2025. Profit before tax (PBT) soared 122.66% to Rs 82.83 crore in Q4 FY25 as compared with Rs 37.20 crore in Q4 FY24. EBITDA stood at Rs 85 crore, registering the growth of 96.8% as compared with Rs 432 crore in Q4 FY24. EBITDA margin was at 27.5% in Q4 FY25 as against 19.2% in Q4 FY24. In Q4 FY25, export stood at 74% and domestic business was at 26%. Naresh Patel, executive chairman & managing director, Ami Organics, said, 'I am delighted to share that FY25 was a transformative year for Ami Organics, as we proudly surpassed Rs 1,000 crore in revenue'a remarkable milestone. This achievement reflects the unwavering dedication of our employees and the invaluable support of our stakeholders, including customers, suppliers, shareholders and all other stakeholders. We extend our heartfelt gratitude for their contributions. Looking ahead to FY26, we anticipate robust growth across all business segments, driving our confidence in achieving 25% revenue growth.' Meanwhile, the company's board recommended of final dividend of Rs 1.5 per equity share for FY25 Ami Organics headquartered at Surat, is a research and development (R&D) driven manufacturer of speciality chemicals focused towards the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients (APIs) and chemicals for New Chemical Entities (NCE), and other specialty chemicals.Powered by Capital Market - Live

Net profit of Ami Organics rose 148.43% to Rs 62.48 crore in the quarter ended March 2025 as against Rs 25.15 crore during the previous quarter ended March 2024. Sales rose 37.13% to Rs 308.48 crore in the quarter ended March 2025 as against Rs 224.96 crore during the previous quarter ended March 2024. For the full year,net profit rose 271.08% to Rs 158.71 crore in the year ended March 2025 as against Rs 42.77 crore during the previous year ended March 2024. Sales rose 40.34% to Rs 1006.88 crore in the year ended March 2025 as against Rs 717.47 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales308.48224.96 37 1006.88717.47 40 OPM %27.5419.19 -23.0517.91 - PBDT90.1342.43 112 242.78130.04 87 PBT82.8337.53 121 216.16113.98 90 NP62.4825.15 148 158.7142.77 271 Powered by Capital Market - Live

AMI Organics announced that the Board of Directors of the Company at its meeting held on 2 May 2025, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 30%) , subject to the approval of the shareholders.Powered by Capital Market - Live

AMI Organics will hold a meeting of the Board of Directors of the Company on 2 May 2025.Powered by Capital Market - Live

Ami Organics' manufacturing facility, Unit II situated at Ankleshwar, which is involved in manufacturing of various intermediates for Active Pharmaceuticals Ingredients, has received Good Manufacturing Practices (GMP) by Pharmaceutical and Medical Devices Agency, Japan (PMDA). Powered by Capital Market - Live